New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:11 EDTRAREUltragenyx reports Q1 EPS (85c), consensus (37c)
Total operating expenses for Q1 were $10.3M compared with $6.7M for the same period in 2013. The increase in total operating expenses is due to the expansion and advancement of Ultragenyx's clinical development pipeline, including the initiation of clinical studies for triheptanoin and recombinant human beta-glucuronidase, as well as increased headcount.
News For RARE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
10:24 EDTRAREUltragenyx management to meet with Jefferies
Subscribe for More Information
November 12, 2014
07:53 EDTRARELeerink to hold a tour
Subscribe for More Information
November 10, 2014
15:53 EDTRARECredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
09:05 EDTRAREUltragenyx reports Q3 EPS (50c), consensus (46c)
Emil D. Kakkis, Ph.D., M.D., CEO and president of Ultragenyx. "We are making great progress with our pipeline and look forward to initiating later-stage development in multiple programs in 2014 and 2015."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use